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tested in clinical trials for their efficacy and tolerability in in-
flammatory skin diseases and chronic wounds. Apart from 
possible fields of application, these peptides appear suited 
as an example of the paradigm of translational medicine for 
skin diseases which is today seen as a ‘two-way road’ – from 
bench to bedside and backwards from bedside to bench. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Antimicrobial peptides (AMPs) are also known as 
host defense peptides. More than 1,200 AMPs from dif-
ferent origins – bacteria, plants, insects, reptiles and 
mammals – have been reported  [1–3] . The ‘nature’s anti-
biotics’ form the first line of mammalian host defense 
against pathogens due to an important function as effec-
tor agents of the innate immune system  [5] . Recent evi-
dence suggests that AMPs also play an important role as 
signaling molecules in linking innate and adaptive im-
mune responses  [6, 7] .
 The small, cationic, amphiphilic peptides built up by 
6–50 amino acids  [1, 4] interact with anionic phospho-
lipid membranes  [4, 8] and thus show a broad-spectrum 
microbicidal activity against both bacteria and fungi  [4] . 
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 Abstract 
 Antimicrobial peptides (AMPs) are small, cationic, amphi-
philic peptides with broad-spectrum microbicidal activity 
against both bacteria and fungi. In mammals, AMPs form the 
first line of host defense against infections and generally 
play an important role as effector agents of the innate im-
mune system. The AMP era was born more than 6 decades 
ago when the first cationic cyclic peptide antibiotics, name-
ly polymyxins and tyrothricin, found their way into clinical 
use. Due to the good clinical experience in the treatment of, 
for example, infections of mucus membranes as well as the 
subsequent understanding of mode of action, AMPs are now 
considered for treatment of inflammatory skin diseases and 
for improving healing of infected wounds. Based on the pre-
clinical findings, including pathobiochemistry and molecu-
lar medicine, targeted therapy strategies are developed and 
first results indicate that AMPs influence processes of dis-
eased skin. Importantly, in contrast to other antibiotics, 
AMPs do not seem to propagate the development of antibi-
otic-resistant micro-organisms. Therefore, AMPs should be 
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By directly targeting and destroying membranes even in 
multidrug-resistant pathogens  [9] , AMPs might contrib-
ute to overcoming the growing problems of antibiotic re-
sistance  [1, 9, 10] , and the shortage of new antibiotics to 
combat multidrug-resistant microbes has led to a new in-
terest in AMPs at large and, in particular, to a renewed 
interest in older AMPs like polymyxins and tyrothricin 
 [12] . In particular, AMPs as multifunctional agents  [13] 
might provide new approaches in the management of in-
fectious/inflammatory skin diseases and thus belong to 
the biggest hopes in curative dermatology.
 AMPs are also well suited as an example of the para-
digm of translational medicine, which means to introduce 
novel, effective therapeutic strategies in the clinic  [14] by 
effectively translating basic research discoveries into clin-
ical tools  [14, 15] . Thus, translational medicine is the in-
terface between preclinical research and clinical develop-
ment. The course of translational medicine was seen as a 
one-way street – with the goal of reaching the path ‘from 
bench to bedside’ as quickly as possible  [14, 16] – although 
it soon became evident that the transfer of knowledge 
from the preclinical to the clinical grounds does not often 
function smoothly. This is partly due to the fact that even 
if preclinical research is being conducted on a large scale 
today, the results are sometimes ignored  [16] and/or can-
not be transferred from test tube or animal model to hu-
man diseases in real life  [17] . Moreover, various regula-
tory obstacles and difficulties impede knowledge transfer 
( [14] ;  fig. 1 ). Recently, it has also been realized that new 
insights gained from observations on clinical grounds 
should flow back to the laboratory to develop new obser-
vation-based therapy strategies  [14] . As a result, today, 
translational medicine is no longer seen as a one-way 
street but rather as a ‘two-way road’ – from bench to bed-
side and backwards from bedside to bench  [14, 18] .
 From a chronological point of view, these two paths 
can also be seen in the development of AMPs for the 
treatment of skin diseases. For example, in the past, there 
already were individual peptides which, after their dis-
covery and characterization, quickly and easily found 
their way from the laboratory to clinical application 
(‘from bench to bedside’) and today – decades after their 
identification – are still being used successfully. Accord-
ing to results of current investigations into molecular 
pathophysiology of skin diseases such as psoriasis, ec-
zema or infected wounds, AMPs such as magainins iso-
lated from African clawed frog  Xenopus laevis  and pro-
tecting the frog’s skin against infections with bacteria 
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 Fig. 1. Milestones of turning laboratory findings into therapy (modified from Kotlan et al. [14], with permis-
sion). 
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and fungi, may allow the rear-entry path ‘from bedside 
to bench’ – from clinical back to preclinical investiga-
tions  [19–22] .
 For other AMPs, researchers try to gain a better un-
derstanding of their role in the human skin and in skin 
diseases in advance to possibly be able to use their thera-
peutic potential in a targeted manner. As of today, it is 
already tempting to imagine that, in the future, the for-
ward-looking ‘from bench to bedside’ path will become 
more important again. This is not only due to the fact that 
preclinical research activity in the area of skin diseases 
will continue to be more effectively organized, but also to 
the fact that all parties involved in the development of 
topical medicaments – basic scientists, pharmacologists, 
pharmacists, clinicians, ethic philosophers, patient advo-
cates and not least the regulatory agencies – are working 
increasingly hand in hand today. As a result, many ob-
stacles in the transfer from preclinical to clinical exper-
tise tend to be removed during the preliminary stages.
 From Bench to Bedside: The Past 
 Historically, the AMP era was born more than 6 de-
cades ago when cationic cyclic peptide antibiotics, name-
ly polymyxins and tyrothricin, were discovered and 
found their way into clinical application relatively quick-
ly, though their modes of action were only uncovered 
years or even decades later. These AMPs had been some-
what forgotten as a result of the discovery of classical an-
tibiotics such as penicillin before they currently began to 
experience a comeback in light of the increasing resis-
tance problem vis-à-vis classical antibiotics and the ex-
treme difficulty in developing truly novel antibiotics  [23] .
 Polymyxins were discovered in 1947 in different spe-
cies of  Bacillus polymyxa  [24] . Only two of them, poly-
myxin B and E (colistin), have been used in clinical prac-
tice. Polymyxins are pentabasic decapeptide antibiotics 
which contain a cycloheptapeptide ring with a C9 or C10 
fatty acid chain through an   -amide linkage. Polymyxins 
are active against Gram-negative bacteria such as  Pseudo-
monas aeruginosa, Klebsiella pneumoniae, Acinetobacter 
baumannii and  Enterobacter species even if they are mul-
tidrug-resistant. The target of antimicrobial activity is as-
sumed to be the bacterial membrane, but there are also 
data supporting a multi-hit hypothesis. Polymyxins have 
also been shown to be an inhibitor of a single subunit 
NADH dehydrogenase (NDH-2) and quinol oxidases 
from certain bacteria making these AMPs promising 
chemotherapeutic agents  [10] . As early reports described 
a high incidence of nephrotoxicity and neurotoxicity  [25, 
26] , polymyxins were gradually withdrawn from clinical 
practice in the 1970s as newer antibiotics with the same 
or a broader antibacterial spectrum considered to be less 
toxic were introduced  [12, 27] . In recent years, we have 
observed a renewed interest in polymyxins supposedly 
due to AMPs’ bactericidal activity even against multi-
drug-resistant bacteria by perturbing membrane integ-
rity and due to actually less frequent and severe toxicity 
of polymyxins than originally reported. Moreover, a 
more careful dosing and the use of critical care services 
allows for risk control  [27] .
 In clinical use, for decades also tyrothricin has gained 
particular interest for the topical treatment of superficial 
infectious skin wounds. Just as polymyxin, tyrothricin’s 
potential was slightly underestimated over the years. Pro-
duced by  Bacillus brevis  [28] , this polypeptide antibiotic 
consists of the two cyclic decapeptides, gramicidine S 
(22%) and tyrocidine A (78%) [29] ( fig. 2 ), both peptides 
commanding broad bactericidal activity against Gram-
positive bacteria due to intercalation of the peptides into 
bacterial membranes. This leads to the formation of hy-
drophilic ion channels rapidly causing cell leakage and 
cell death  [30] . The antimicrobial efficacy of tyrothricin 
seems to be the result of synergistic effects of tyrocidine 
(amino acids, purines, pyrimidines and phosphates) and 
gramicidine (increased potassium outflow)  [31] . In addi-
tion, gramicidin disrupts vital functions of the bacterial 
cell by uncoupling the phosphorylation of the respiratory 
chain  [31] .
 More recent publications have shown that tyrothricin 
in vitro shows a clinically relevant antibacterial activity 
against Gram-positive bacteria isolated from the normal 
flora of the respiratory tract with minimal inhibitory 
concentrations (MIC 90 ) ranging from 0.046 mg/l for 
 Streptococcus pyogenes to 3.12 mg/l for  Staphylococcus 
aureus , methicillin-susceptible (MSSA) and – particular-
ly noteworthy – methicillin-resistant and multidrug-re-
sistant strains of  S. aureus  [32, 33] . In vitro, tyrothricin is 
also active against streptococci including enterococci  [32, 
34] and yeasts like  Candida albicans  [35] .
 Besides its antibacterial activity, tyrothricin is also 
able to inactivate viruses like Sendai virus  [36] , herpes 
simplex virus (HSV)  [37] and human immunodeficiency 
virus (HIV)  [38] . Toxicity towards eukaryotic cells  [39] 
restricts the use of tyrothricin as antibiotic to local appli-
cation  [40] , in particular for the treatment of infected 
skin and infected oropharyngeal mucous membranes.
 In the treatment of infectious small, superficial 
wounds, tyrothricin may find its place; also, resistance 
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development to tyrothricin seems to be a rare event  [34] . 
For example, the prolonged use of tyrothricin tooth paste 
over 2 years by 99 subjects neither led to an increase in 
the numbers of tyrothricin-resistant microorganisms nor 
to an increase in cross-resistance to penicillin, strepto-
mycin, tetracyclines and chloramphenicol  [41] . A recent 
study has demonstrated that Gram-positive bacteria in-
cluding staphylococci and streptococci (including en-
terococci), as well as  Corynebacterium  spec. and yeast 
species, namely  C. albicans and  Candida parapsilosis, still 
turn out to be highly susceptible to tyrothricin, and sus-
ceptibility of formerly sensitive Gram-positive bacterial 
and yeast strains could be preserved over the years, indi-
cating that the risk of resistance development against top-
ically applied tyrothricin is negligible (unpublished data 
Engelhard). Microbiological data are in accordance with 
clinical data. In detail, the efficacy and tolerability of an 
antiseptic wound powder based on tyrothricin was dem-
onstrated in a prospective, randomized multicenter trial 
with 131 patients with posttraumatic and surgical cuta-
neous lesions. Tyrothricin powder proved superior to ve-
hicle concluding from the radius of the lesions (p = 0.016) 
as well as the wound index (p = 0.005), while the tolerabil-
ity of verum and vehicle did not differ  [42] . Pertinent 
findings together with the lacking evidence for the devel-
opment of resistance are reflected by the drug approval 
for topical formulations incorporating tyrothricin 0.1% 
(Tyrosur  Puder/Gel) for bacterially superinfected su-
perficial wounds due to susceptible microorganisms. 
This is a good example of how an ‘old’ medicament can 
still be used and, in fact, is still being used today to treat 
skin diseases – even though initially the exact mode of 
action was not known.
 From Bedside to Bench: The Present 
 Reflecting the good clinical experience with the use of 
‘old’ AMPs such as tyrothricin and the subsequent un-
derstanding of their mechanisms of action, the potential 
of the ‘natural antibiotics’ at large has come into focus 
with respect to the treatment of infectious skin diseases. 
Owing to the significantly improved possibilities of mo-
lecular medicine, AMPs’ immunomodulatory effects on 
the innate immune system and the adaptive immune re-
sponse have been revealed, and AMPs thus might be used 
to treat inflammatory skin diseases at large and, in par-
ticular, to improve wound healing. Because of the new 
understanding of translational medicine as a ‘two-way 
road’ and because of the many regulatory obstacles and 
difficulties that currently stand in the way of a transfer of 
knowledge from the laboratory to the hospital  [14] , the 
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first step in dermatology’s approach today is understand-
ing the role of AMPs in human skin. Based on these find-
ings, targeted therapy strategies are developed which fo-
cus on the mechanism of action. In a third step, the in-
sights gained in preclinical trials are supposed to be put 
into practice, and the AMPs that modulate the defined 
disease-related processes will have to be tested in clinical 
studies for their efficacy and tolerability. The current sta-
tus of research, however, is an improved understanding 
of the physiological activity of AMPs in human skin – 
and thus of their role in infectious and inflammatory 
skin diseases as well.
 AMPs in Invertebrate and Vertebrate Skin 
 AMPs have been found in bacteria, invertebrates and 
vertebrates and show activity in organisms with or with-
out complex adaptive immune system  [43, 44] . The ob-
servation that AMPs are locally produced in the epithe-
lium after invertebrates like the moth  Hyalophora cecro-
pia, the fruit fly  Drosophila melanogaster  and at least 150 
further insects  [43, 45] have had contact with microbes 
supports the hypothesis that AMPs are part of a kind of 
primary ‘chemical’ defense system which – in addition to 
the physical barrier provided by the skin – protects inter-
faces from infection with pathogenic microorganisms. 
This hypothesis was supported in the late 1980s when the 
first inducible AMPs were isolated in vertebrates  [19] – 
for example the AMP magainin. It is secreted in the neu-
roepithelial glands of the frog’s skin upon stimulation 
with noradrenalin  [46] . Magainin commands a wide 
spectrum of antimicrobial activity against Gram-positive 
and Gram-negative bacteria and fungi  [21] , antiviral 
properties  [47] and possibly anti-spermicidal activity 
[48]. Binding to anionic phospholipids on the outer leaf-
let of bacterial membranes, magainin leads to perturba-
tion of membrane permeability and subsequently cell ly-
sis  [20, 21, 49–52] . Today, magainins and their analogues 
are promising agents for future therapeutic approaches.
 AMPs in Human Skin 
 Human skin is permanently exposed to microorgan-
isms but rarely infected, thus showing a natural resis-
tance towards pathogens. One, if not the main, reason for 
this might be the existence of constitutively and inducibly 
produced AMPs  [43] . In fact, human skin is a major 
source of AMPs  [44] with keratinocytes as the main pro-
ducers  [6] as cutaneous AMPs include the main groups of 
defensins, cathelicidins, dermcidin (DCD) and other 
small peptides such as neuropeptides and chemokines 
 [44] . For several years, there has been a strong interest in 
better understanding the role of constitutively expressed 
and especially inducible AMPs in infectious/inflamma-
tory diseases to determine their modes of action (‘from 
bedside to bench’) with the aim of being able, in the long 
run, to make targeted use of the therapeutic potential of 
these peptides in skin diseases (‘from bench to bedside’). 
In the following section, we briefly present the most im-
portant human AMPs and subsequently shed light on 
their role in infectious/inflammatory skin diseases.
 Defensins 
 Human defensins are AMPs of 30–40 amino acids 
with a molecular weight of about 3–4 kDa; six cysteines 
form intramolecular disulfide bonds  [4] . Defensins can 
be classified as   -,   - and   -forms based on their typical 
spaces between the cysteine residues and their disulfide 
pattern. Neutrophils express   -defensins  [53] , whereas 
keratinocytes are the source for   -defensins  [6] . Up to 
now, six different human   -defensins have been de-
scribed: HPN (human neutrophil peptide)-1, HPN-2, 
HPN-3, HPN-4, as well as HD (human defensin)-5 and 
HD-6, with the latter two only being constitutively pro-
duced in Paneth cells (long-lived secretory cells) in the 
small intestine  [54] and actively secreted in the urogenital 
tract; HD-5 is additionally expressed in female reproduc-
tive tissues  [55] . To date, four different   -defensins ex-
pressed by keratinocytes have been identified and char-
acterized: HBD (human   defensin)-1 to -4  [44] . HBD-2 
and -3 are highly induced by Gram-positive bacteria and 
inducibility of HBD-3 influences the severity of Gram-
positive skin infection  [56] .   -defensins were primarily 
found in non-human primates  [57] but have not been 
identified in humans so far.
 Both   - and   -defensins show a broad antibacterial 
activity against Gram-positive and Gram-negative bacte-
ria and also have antifungal and antiviral (adenovirus, 
papilloma virus, HIV and HSV) activity which derives 
from different modes of action including modulation of 
receptors on immunocompetent cells and inhibiting 
multiple steps of viral infectivity  [44] . As with AMPs in 
general, the presumed mechanism of bacterial killing is 
binding of positively charged defensins to negatively 
charged bacterial membranes resulting in membrane 
permeabilization  [44] .
 Cathelicidin 
 Cathelicidin peptides, including the human cathelici-
din LL-37, mostly form an   -helical structure; cationic 
charge enables these AMPs to bind to negatively charged 
bacterial membranes  [44] . In humans, only cathelicidin 
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LL-37 is expressed by neutrophils, mast cells and kerati-
nocytes (after an inflammatory stimulus) as the major 
sources  [6] . LL-37 shows a broad activity against Gram-
positive and Gram-negative bacteria and works synergis-
tically with other AMPs like   -defensins  [58] . Besides its 
antimicrobial effect, LL-37 is able to chemoattract mast 
cells, neutrophils, monocytes and T cells to sites of in-
flammation and additionally modulates immune re-
sponses and re-epithelization of skin wounds  [59] , mak-
ing LL-37 an interesting peptide for therapeutic interven-
tion in infectious/inflammatory diseases  [60] .
 Dermcidin 
 DCD was identified in the eccrine gland and appears 
to be the principal sweat AMP  [61] . Other than defensins 
and cathelicidins, DCD is constitutively secreted in hu-
man sweat and is not inducible by injury and dermal in-
flammation  [62] . Proteolytic cleavage of a 9.3-kDa pre-
cursor results in a peptide made of 47 amino acids (DCD-
1) which – in low micromolar concentrations – shows 
antimicrobial activity against  S. aureus, Enterococcus 
faecalis, Escherichia coli and  C. albicans under in vitro 
conditions resembling human sweat  [61] . Contrary to 
defensins and cathelicidins, DCD-1 most likely does not 
kill bacteria by permeabilizing their membranes as 
DCD-1 is an anionic peptide showing a flexible structure 
with   -helices and   -sheets, depending on the environ-
mental conditions  [63] . The amount of DCD-1 in human 
sweat, which is 1–10   g/ml in healthy humans  [61] , ap-
pears to be reduced in patients with atopic dermatitis 
 [43] .
 Other AMPs 
 Besides defensins, cathelicidins and DCD, human 
skin expresses other AMPs such as proteinase inhibitors, 
chemokines and neuronal proteins/peptides with RNase 
7 and psoriasin (S100A7) as the most prominent repre-
sentatives  [44] . The highly basic 14.5-kDa protein RNase 
7  [64] is one of the major heparin-binding proteins in 
healthy human stratum corneum  [43] . In addition to its 
relative abundance in human skin, the expression of 
RNase 7 can further be induced by proinflammatory cy-
tokines and possibly by bacteria  [64, 65] . RNase 7 from 
human skin shows a broad activity against Gram-nega-
tive  (E. coli  and P. aeruginosa) and Gram-positive bacte-
ria  (Propionibacterium acnes  and S. aureus) as well as 
against the yeast  C. albicans  [44] . In this sense, RNase 7 
is one of the most potent and most efficacious human an-
timicrobial proteins known so far  [43] . Recently, another 
member of the RNase family, RNase 8, has been identi-
fied as a novel AMP with broad-spectrum microbicidal 
activity  [66] .
 Psoriasin is a calcium- and zinc-binding peptide that 
is expressed in healthy skin stratum corneum  [44, 67] and 
in even higher amounts in psoriatic skin  [68] . Psoriasin 
is the principal  E. coli -bactericidal component and one of 
the innate barriers of healthy skin;  P. aeruginosa and  S. 
aureus are less susceptive  [43, 44, 67] .
 AMPs in Skin Diseases 
 What makes AMPs especially interesting for applied 
dermatology is the relation between the severity of vari-
ous skin diseases and the expression of AMPs. Correla-
tions can be positive or inverse  [6, 44] . For example, there 
is an association between lowered levels of AMPs in burns 
as well as chronic wounds compared to normal skin. A 
reduced amount of DCD in the sweat coincides with an 
impaired innate defense of human skin, while AMP over-
expression in human skin appears to be accompanied by 
an increased protection against infection in psoriasis, ro-
sacea or in other inflammatory skin diseases  [6] . These 
findings indicate that AMPs have a potential for thera-
peutic use. Before practical use, however, the role of a par-
ticular peptide in various skin diseases should be pre-
cisely known.
 AMPs and Psoriasis 
 Psoriasis is an inflammatory non-infectious skin dis-
ease with typical inflammatory plaques reflecting hyper-
proliferation of the epidermis resulting in massive pro-
duction of scale  [6, 69] . Psoriasis is considered to be an 
autoimmune disease as in psoriatic lesions, high levels of 
proinflammatory cytokines, chemokines as well as acti-
vated T cells and antigen-presenting cells can be found. 
Interestingly, in the skin of patients with psoriasis, almost 
all known AMPs, such as the   -defensins HBD-2 and -3, 
the cathelicidin LL-37, psoriasin, RNase 7 as well as other 
AMPs (such as ALP/SLP1, Elafin/SKALP), are highly up-
regulated  [6, 65] (see also  fig. 3 ). The overexpression of 
AMPs accompanied by the synergistic interaction seems 
to be one major reason for the observed lowered suscep-
tibility of psoriatic skin to cutaneous bacterial infections 
 [70] .
 Although the mechanism of AMP induction in psori-
atic skin is not completely understood, there seems to be 
a strong association with increased levels of cytokines 
like IL-1  and IL-6, as well as IFN-  and -   [11, 71–74] . 
This hypothesis is supported by cathelicidin LL-37 in-
duction of IFN-   [75] .
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 AMPs and Rosacea 
 Rosacea is a common chronic, often underdiag-
nosed, skin disease of uncertain etiology. The various 
clinical manifestations associated with this disease 
most frequently occur in the light-skinned Caucasian 
population, in persons between 30 and 50 years of age 
 [76, 77] . The dermatological manifestations of rosacea 
mainly affect cheek, nose, chin, and central forehead. 
The earliest symptoms associated with rosacea are in-
termittent central facial f lushing and erythema. Fur-
thermore, the disease may be linked to ocular manifes-
tations  [78] . Until today, the pathogenesis of rosacea is 
not known in detail, yet evidence has been accumulat-
ing that rosacea with its common symptoms, such as 
inflammatory lesions, erythema, teleangiectasia, phy-
matous changes and ocular symptoms, is of inflamma-
tory nature  [79] .
 Most recently, it could be shown that symptoms of ro-
sacea are exacerbated by factors that trigger innate im-
mune responses, such as the release of cathelicidin AMPs 
produced by keratinocytes  [80] . Clearly, there is a role of 
cathelicidin in skin inflammatory responses as individu-
als with rosacea express cathelicidin LL-37 at abnormally 
high levels in their facial skin, and specific proteolyti-
cally processed forms of cathelicidin peptides found in 
rosacea differ from those found in normal individuals 
 [79, 81] . These forms, but not those from healthy skin, are 
able to induce the release of the proinflammatory IL-8 
from keratinocytes  [6] . This means that in the pathogen-
esis of rosacea, cathelicidin peptides likely are abnormal-
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 Fig. 3. Illustration of the protective function of AMPs in normal skin ( a ) and infected and/or inflamed skin such as in psoriasis ( b ) 
(from Schittek et al. [6], with permission). 
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ly processed to forms that induce inflammation  [7] , pro-
viding evidence that the elevated levels of cathelicidins 
contribute to the chronic inflammatory reaction in the 
skin of patients with rosacea  [6] .
 AMPs and Acne Vulgaris 
 Acne vulgaris is a chronic inflammatory disorder of 
the pilosebaceous units widely affecting adolescents and 
young adults. Characteristic of this skin disorder is the 
formation of comedones, papules, pustules, nodules and/
or cysts as a result of obstruction and inflammation. The 
pathogenesis, as far as already known, involves excess se-
bum production, follicular hyperproliferation, inflam-
matory reactions and colonization with  P. acnes  [82] . In 
lesional and perilesional epithelium of patients with acne 
vulgaris, a marked upregulation of human   -defensins 
(HBD-1 and HBD-2) is found, in the case of HBD-2 most 
likely triggered by  P. acnes and mediated by the Toll-like 
receptor (TLR) signaling pathway  [83] . The role of other 
AMPs remains to be clarified, but it is known that   -de-
fensins, cathelicidin LL-37 and psoriasin expressed in ke-
ratinocytes and sebocytes are able to kill  P. acnes making 
these AMPs possible future candidates for therapeutic in-
tervention oriented at the pathogenesis of acne. Another 
AMP interesting for the future treatment of acne is omi-
ganan, a novel, synthetic, cationic analogue of the AMP 
indolicidin that was originally purified from the cyto-
plasmic granules of bovine neutrophils  [84] . It demon-
strates in vitro activity against a wide variety of microor-
ganisms, including Gram-positive and Gram-negative 
bacteria and fungi  [84] . Omiganan is the most advanced 
agent in the frontline of applications of AMPs  [85] and is 
currently clinically tested for the treatment of acne and 
rosacea.
 AMPs and Atopic Dermatitis 
 Atopic dermatitis is a complex chronic inflammatory 
skin disease which is characterized by xerosis, pruritus 
(itch) and erythematous lesions with increased transepi-
dermal water loss  [86] . Atopic dermatitis significantly af-
fects the quality of life of patients and their families. New 
insights into the pathophysiology of the disease refer to 
an important role of structural abnormalities in the epi-
dermis associated with immune dysregulation  [87] . Typ-
ically, patients with atopic dermatitis show a predisposi-
tion to colonization or infection by various microorgan-
isms, in particular  S. aureus and HSV A  [87] . Some 
studies analyzing AMPs in lesional skin show that, in 
contrast to psoriasis, rosacea and acne vulgaris, atopic 
dermatitis is characterized by less expression of AMPs, 
especially of cathelicidin LL-37 and HBD-2  [72, 88, 89] . It 
has been hypothesized that a reduced induction of AMPs 
in atopic dermatitis may contribute to the increased sus-
ceptibility of skin infections, in particular with  S. aureus 
 [72, 90] . However, most of the studies investigating AMP 
expression levels in atopic dermatitis skin have compared 
these levels primarily to those in psoriatic skin, not to 
healthy skin  [72, 88, 89] . Gläser et al.  [91]  observed that 
the expression and secretion of psoriasin was more 
strongly induced in atopic dermatitis skin compared to 
healthy skin, indicating that AMP expression is not gen-
erally reduced in atopic dermatitis. An enhanced expres-
sion of RNase 7, psoriasin and HBD-2 and HBD-3 in 
atopic dermatitis lesional skin compared to non-lesional 
skin and healthy controls is possibly triggered by a dis-
turbed skin barrier. Thus, the role of AMPs in atopic der-
matitis, especially with regard to the control of  S. aureus 
colonization, remains to be elucidated in more detail  [92] .
 AMPs and Skin Injury/Wounds 
 The functional role of constitutively and inducibly ex-
pressed AMPs after skin injury and in chronic wounds 
also needs further analysis. At present, data from the lit-
erature suggest that AMPs, such as cathelicidin LL-37, 
HBD-2, HBD-3, psoriasin and RNase 7, are upregulated 
after skin injury, including burnt skin  [5, 21, 44] , whereas 
cathelicidin expression is low or even absent in the chron-
ic wound stage  [6, 44] . As LL-37 has a direct effect on 
wound healing by promoting neovascularization and an-
giogenesis  [5, 93] , this AMP seems to be the most promis-
ing agent for future therapeutic approaches in order to 
antagonize impaired wound healing.
 AMPs and Other Skin Diseases 
 There are also other skin diseases with an altered 
AMP expression, but pertinent data are somewhat frag-
mentary and not completely consistent as yet. In general, 
inflammatory skin diseases seem to be associated with 
an increased expression of AMPs. For example, HBD-2 
has been shown to be upregulated in superficial follicu-
litis  [94] and HBD-1 to HBD-3 mRNA levels in localized 
scleroderma  [95] . High expression of HPN-3 has been 
found in cutaneous T-cell lymphoma patients  [96] . Con-
dyloma acuminatum and verruca vulgaris are associated 
with an increase in cathelicidin LL-37 expression  [97] . 
Altogether, the precise function of AMPs in the men-
tioned skin diseases, however, remains to be further clar-
ified.
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 From Bench to Bedside: The Future 
 On the basis of the new insights into the cellular and 
molecular roles of AMPs in human skin and in certain 
skin diseases described above, it is to be expected that a 
second wave of new ‘from bench to bedside’ AMPs will 
contribute to our therapeutic armamentarium within a 
few years  [23] .
 Several AMPs are currently undergoing laboratory 
testing and the application of these peptides in in vitro 
experiments and animal models is seemingly successful 
 [45] . However, despite undeniable successes in the pre-
clinical area, only few AMPs have reached the phase of 
testing in clinical trials so far  [45, 98, 99] . At present, four 
AMPs were successful in therapeutic clinical trials  [5] . 
Pexiganan, a derivative of magainin, which has been de-
veloped for the treatment of infected foot ulcers in pa-
tients with diabetes mellitus and which entered phase III 
trials  [45] and has been shown to be equally effective as 
oral ofloxacin, was finally not approved by the US Food 
and Drug Administration  [98] . Omiganan has completed 
one phase II study for the treatment of rosacea and two 
phase II studies for the treatment of acne, the latter dem-
onstrating evidence of efficacy against all acne lesion 
types  [100] . One possible reason for the fact that clinical 
studies and, even more so, the large phase III studies with 
AMPs are very rare is the still limited knowledge on sta-
bility of peptides, although stability problems can be 
largely overcome by adding protease inhibitors  [45] . A 
possibly even more important reason that so few AMPs 
have been clinically tested up to now appears to be a pos-
sible cytotoxicity of AMPs  [45, 101] . For example, the 
mammalian AMP protegerin-1 reduced the bacterial 
count in a murine sepsis model, yet it also reduced the 
survival rate – probably by inducing endotoxin release 
and, as a result, modifications in the host innate immune 
response  [102] .
 Despite the problems of cytotoxicity of AMPs, in top-
ical treatment of skin diseases, they are certainly less sig-
nificant than in the systemic therapy of infectious and/or 
inflammatory diseases. However, it is important to men-
tion in this regard that, although tyrothricin can only be 
administered topically because of its systemic toxicity, it 
is still effective  and well tolerated in the therapy of skin 
disease. Recently, strategies have increasingly been de-
vised aiming at a reduced cytotoxicity of AMPs and, if 
possible, at the same time at an improved antimicrobial 
activity  [5] .
 One of these strategies is to make designer peptides 
such as P-novispirin G10  [103] . They exhibit low cyto-
toxic activity and often at the same time show an im-
proved therapeutic efficacy, as it has been shown for a 
bactericidal immunomodulatory fusion peptide of HBD-
3 with a mannose-binding lectin, even against MRSA 
 [104] . Another promising strategy is to develop analogues 
or truncated molecules of human AMPs, e.g. of cathelici-
din LL-37, being less hemolytic and toxic as well as more 
effective compared to native LL-37  [105, 106] . Finally, 
some scientists substitute several L-amino acids in AMPs 
to achieve a reduced toxicity  [107] or combine conven-
tional antibiotics with AMPs in order to ensure high an-
timicrobial activity and low toxicity  [5, 108] while at the 
same time reducing the risk of bacterial resistance. Al-
though it cannot as yet be said which of these strategies 
will ultimately succeed and will help to bring new AMPs 
or their derivatives to the clinic to treat infectious and/or 
inflammatory skin diseases, the fact remains that inten-
sive work is being done on these issues worldwide.
 Conclusion 
 Based on new insights into the cellular and molecular 
roles of AMPs in human skin and in infectious/inflam-
matory skin diseases, it is to be expected that AMPs or 
their recombinant analogues will contribute to our ther-
apeutic armamentarium within a few years. Strategies 
have increasingly been devised aiming at a reduced cyto-
toxicity of AMPs and ideally at the same time at an im-
proved antimicrobial activity. Nevertheless, presently 
‘old’ AMPs, such as tyrothricin, are still of clinical impor-
tance in the treatment of infectious skin diseases and may 
experience a renaissance as natural antibiotics.
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